Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial - 24/02/22
, Frantz Foissac, PhD c, d, Hendy Abdoul, MD c, d, Guillaume Masson, MSc c, Laure Choupeaux, MSc c, Eric Dufour, PhD c, Nabil Gastli, PharmD e, Severine Mercier Delarue, MSc a, Marie Laure Néré, MSc a, Marine Minier, MSc a, Audrey Gabassi, MSc a, Maud Salmona, PhD a, f, Malika Seguineau g, Sarah Schmitt g, Sébastien Tonglet, MSc h, Alexis Olivier, MSc h, Claire Poyart, ProfMD i, j, Jerôme Le Goff, ProfPhD a, f, Xavier Lescure, ProfMD k, m, Solen Kernéis, MD l, n, o, *, Jean-Marc Tréluyer, ProMD c, *and the
SPRING study group†
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Background |
Mass indoor gatherings were banned in early 2020 to prevent the spread of SARS-CoV-2. We aimed to assess, under controlled conditions, whether infection rates among attendees at a large, indoor gathering event would be similar to those in non-attendees, given implementation of a comprehensive prevention strategy including antigen-screening within 3 days, medical mask wearing, and optimised ventilation.
Methods |
The non-inferiority, prospective, open-label, randomised, controlled SPRING trial was done on attendees at a live indoor concert held in the Accor Arena on May 29, 2021 in Paris, France. Participants, aged 18–45 years, recruited via a dedicated website, had no comorbidities, COVID-19 symptoms, or recent case contact, and had had a negative rapid antigen diagnostic test within 3 days before the concert. Participants were randomly allocated in a 2:1 ratio to the experimental group (attendees) or to the control group (non-attendees). The allocation sequence was computer-generated by means of permuted blocks of sizes three, six, or nine, with no stratification. The primary outcome measure was the number of patients who were SARS-CoV-2-positive by RT-PCR test on self-collected saliva 7 days post-gathering in the per-protocol population (non-inferiority margin <0·35%). This trial is registered with ClinicalTrials.gov, NCT04872075.
Findings |
Between May 11 and 25, 2021, 18 845 individuals registered on the dedicated website, and 10 953 were randomly selected for a pre-enrolment on-site visit. Among 6968 who kept the appointment and were screened, 6678 participants were randomly assigned (4451 were assigned to be attendees and 2227 to be non-attendees; median age 28 years; 59% women); 88% (3917) of attendees and 87% (1947) of non-attendees complied with follow-up requirements. The day 7 RT-PCR was positive for eight of the 3917 attendees (observed incidence, 0·20%; 95% CI 0·09–0·40) and three of the 1947 non-attendees (0·15%; 0·03–0·45; absolute difference, 95% CI −0·26% to 0·28%), findings that met the non-inferiority criterion for the primary endpoint.
Interpretation |
Participation in a large, indoor, live gathering without physical distancing was not associated with increased SARS-CoV-2–transmission risk, provided a comprehensive preventive intervention was implemented.
Funding |
French Ministry of Health.
Translation |
For the French translation of the abstract see Supplementary Materials section.
Le texte complet de cet article est disponible en PDF.Plan
Vol 22 - N° 3
P. 341-348 - mars 2022 Retour au numéro
Article précédent
- Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
- Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana-Arri, Gustavo Jose Aroca Martinez, Marc Bonten, Reynaldo Chandler, Gonzalo Corral, Eddie Jan Louis De Block, Lucie Ecker, Julian Justin Gabor, Carlos Alberto Garcia Lopez, Lucy Gonzales, María Angélica Granados González, Nestor Gorini, Martin P Grobusch, Adrian D Hrabar, Helga Junker, Alan Kimura, Claudio F Lanata, Clara Lehmann, Isabel Leroux-Roels, Philipp Mann, Michel Fernando Martinez-Reséndez, Theresa J Ochoa, Carlos Alberto Poy, Maria Jose Reyes Fentanes, Luis Maria Rivera Mejia, Vida Veronica Ruiz Herrera, Xavier Sáez-Llorens, Oliver Schönborn-Kellenberger, Mirjam Schunk, Alexandra Sierra Garcia, Itziar Vergara, Thomas Verstraeten, Marisa Vico, Lidia Oostvogels, HERALD Study Group, Luciano Lovesio, Fabián Diez, Franco Grazziani, Maria Cristina Ganaha, Viviana Judith Zalatnik, Ricardo Julio Dittrich, Lidia Espínola, Sandra Lambert, Andrea Longhi, Claudia Vecchio, María Mastruzzo, Alberto Fernandez, Silvina Borchowiek, Roberto Potito, Rodolfo Andres Ahuad Guerrero, Fernando Martin Guardiani, Sofia Castella, Monica Foccoli, Aldana Pedernera, Ariel Braida, Virginia Durigan, Carolina Martella, Antonela Bobat, Bruno Emilio Boggia, Sergio Andrés Nemi, Javier Gerardo Tartaglione, Fabián César Piedimonte, Jessie De Bie, Humberto Reynales Londoño, Paula Andrea Rodríguez Ordoñez, Johanna Marcela García Cruz, Leonardo Bautista Toloza, Margot Cecilia Ladino González, Adriana Pilar Zambrano Ochoa, Iñigo Prieto Pradera, Daniela Torres Hernandez, Diana Patricia Mazo Elorza, Maria Fernanda Collazos Lennis, Beatriz Vanegas Dominguez, Lina Marianur Solano Mosquera, Rolf Fendel, Wim Alexander Fleischmann, Erik Koehne, Andrea Kreidenweiss, Carsten Köhler, Meral Esen, Carola Horn, Sandra Eberts, Arne Kroidl, Kristina Huber, Verena Thiel, Sonia Mazara Rosario, Gilda Reyes, Laura Rivera, Yeycy Donastorg, Flavia Lantigua, Dania Torres Almanzar, Rosalba Candelario, Lourdes Peña Mendez, Nadia Rosario Gomez, Antonio Portolés-Pérez, Ana Ascaso del Río, Leonor Laredo Velasco, Maria Jesus Bustinduy Odriozola, Igor Larrea Arranz, Luis Ignacio Martínez Alcorta, María Isabel Durán Laviña, Natale Imaz-Ayo, Susana Meijide, Aitor García-de-Vicuña, Ana Santorcuato, Mikel Gallego, Gloria Mayela Aguirre-García, Jocelyn Olmos Vega, Pablo González Limón, Andrea Vázquez Villar, Jaime Chávez Barón, Felipe Arredondo Saldaña, Juan de Dios Luján Palacios, Laura Julia Camacho Choza, Eduardo Gabriel Vázquez Saldaña, Sandra Janeth Ortega Dominguez, Karen Sofia Vega Orozco, Ivonne Aimee Torres Quiroz, Alejandro Martinez Avendaño, Javier Herrera Sanchez, Esperanza Guzman, Laura Castro Castrezana, Guillermo Miguel Ruiz Palacios y Santos, Ronald Frank Jacobus de Winter, Hanna K de Jonge, Jenny L Schnyder, Wim Boersma, Lisa Hessels, Remco Djamin, Simone van der Sar, Rodrigo DeAntonio, Moisés Peña, Gabriel Rebollon, Marianela Rojas, Johnny Escobar, Bruno Hammerschlag Icaza, Digna Y Wong T, Paulo Barrera Perigault, Sergio Ruiz, Milagros Chan, Dommie Janneth Arias Hoo, Ana I Gil, Carlos R Celis, Maria Pia Balmaceda, Omar Flores, Mayra Ochoa, Bia Peña, Carolina de la Flor, Camille María Webb, Enrique Cornejo, Fatima Sanes, Valerie Mayorga, Gladys Valdiviezo, Suzanne Pamela Ramírez Lamas, Gustavo Alberto Grandez Castillo, Javier R Lama, Milagros Erika Matta Aguirre, Lesly Angela Arancibia Luna, Óscar Carbajal Paulet, José Zambrano Ortiz, Anais Camara, Fernanda Guzman Quintanilla, Carmen Diaz-Parra, Jose Morales-Oliva, Rubelio E Cornejo, Sheby A Ricalde, Jhonny Vidal, Luis Rios Nogales, Darline Cheatham-Seitz, Giorgia Gregoraci, Alain Brecx, Lisa Walz, Dominik Vahrenhorst, Tobias Seibel, Gianluca Quintini
- Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study
- Devashish Desai, Adil Rashid Khan, Manish Soneja, Ankit Mittal, Shivdas Naik, Parul Kodan, Ayan Mandal, Ganesh Tarachand Maher, Rohit Kumar, Ayush Agarwal, Naveen R Gowda, Vikas H, Parmeshwar Kumar, Shivam Pandey, R M Pandey, Arvind Kumar, Animesh Ray, Pankaj Jorwal, Neeraj Nischal, Aashish Choudhary, Megha Brijwal, Karan Madan, Rakesh Lodha, Sanjeev Sinha, Lalit Dar, Naveet Wig, Randeep Guleria
Bienvenue sur EM-consulte, la référence des professionnels de santé.